151823-14-2
151823-14-2 結(jié)構(gòu)式
基本信息
N-[1-[(2R,3S,4S,5R)-3-氰基-4-羥基-5-(羥甲基)氧雜環(huán)戊-2-基]-2-氧代嘧啶-4-基]十六酰胺
CS-682
CYC 682
CS-2513
Sapacitabine
10G, 50G, 100G, 1KG
Sapacitabine (CYC682)
CYC 682
CYC-682
CS-682
CS682
CS 682
1-(2-Deoxy-2-cyano-β-D-arabinofuranosyl)cytosine
1-(2-C-Cyano-2-deoxy-β-D-arabino-pentofuranosyl)cytosine
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/08/19 | HY-16445 | N-[1-[(2R,3S,4S,5R)-3-氰基-4-羥基-5-(羥甲基)氧雜環(huán)戊-2-基]-2-氧代嘧啶-4-基]十六酰胺 Sapacitabine | 151823-14-2 | 5mg | 750元 |
| 2024/08/19 | HY-16445 | N-[1-[(2R,3S,4S,5R)-3-氰基-4-羥基-5-(羥甲基)氧雜環(huán)戊-2-基]-2-氧代嘧啶-4-基]十六酰胺 Sapacitabine | 151823-14-2 | 10mM * 1mLin DMSO | 810元 |
| 2024/08/19 | HY-16445 | N-[1-[(2R,3S,4S,5R)-3-氰基-4-羥基-5-(羥甲基)氧雜環(huán)戊-2-基]-2-氧代嘧啶-4-基]十六酰胺 Sapacitabine | 151823-14-2 | 10mg | 1300元 |
常見(jiàn)問(wèn)題列表
nucleoside analog
Concentrations of Sapacitabine required to achieve an IC 50 range from 3±0.6?μM for the colon cancer cell line HCT116 to 67±14?μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G 2 /M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC 50 20±6 μM). In the docetaxel/Sapacitabine combinations, synergistic effects (CI<1) are observed when docetaxel is given before Sapacitabine in both cell lines.
On Day 14, the Sapacitabine (5?mg/kg)+vorinostat (33?mg/kg) group has a mean tumour volume of 245?mm 3 and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15?mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107?mm 3 and a TGI of 112%.